Trial reportScientific reports2022
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.Frontiers in public health · 2023Pooled it
- Biometric Strategies to Improve Vaccine Immunogenicity and Effectiveness.Biomimetics (Basel, Switzerland) · 2025Review
- Comparative duration of neutralizing responses and protections of COVID-19 vaccination and correlates of protection.Nature communications · 2025Article
- Effect of heterologous intranasal iNCOVACCCommunications medicine · 2025Article
- An Explorative Study on Knowledge, Attitudes, and Coronavirus Disease 2019 Vaccine Intention among Parents in India.The American journal of tropical medicine and hygiene · 2025Article
- Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months.Frontiers in medicine · 2025Article
- Receptor Binding Domain-Specific B Cell Memory Responses Among Individuals Vaccinated Against SARS-CoV-2.Vaccines · 2024Article
- Transmission risks of Omicron BA.5 following inactivated COVID-19 vaccines among children and adolescents in China.Communications medicine · 2024Article
- Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.The Indian journal of medical research · 2024Article
- Acceptance of COVID-19 vaccine booster dose among the people of Bangladesh: A cross-sectional study.Heliyon · 2023Article
- Immunogenicity of ChAdOx1 (Covishield) Booster Dose in Healthcare Providers: A Pre-Post Study.Cureus · 2023Article
- Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELDNPJ vaccines · 2023Article
- Article
- Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (CovaxinNPJ vaccines · 2023Article
- Article
- Article
- SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.Vaccines · 2023Review
- SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization.Vaccines · 2023Article
- An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals.iScience · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a comprehensive report on immunogenicity of COVAXIN
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.